Clinical trials: Human Immunodeficiency Virus Transmission
Sexual Risk Behavior for HIV-Infection
Effect Study of a Theory-Based Internet Intervention on Safe-Sex Practices
The purpose of this study is to examine the efficacy of a theory based, online tailored intervention on stimulating safe-sex practices among men who have sex with men (MSM).
- Trial name
- NCT00378885
- Testing
- Cognitive-behavioral tailored intervention
- Where
- Netherlands
- Volunteers
- 642 people, healthy volunteers welcome
- Sponsor
- Public Health Service of Amsterdam
HIV Infections
Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy
Some HIV-infected individuals have a white blood cell marker known as HLA-B*57 that appears to help control the progress of the disease; however, not all who have the HLA-B*57 marker are able to control the infection.
- Trial name
- NCT00559416
- Testing
- Cell Transfer
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections
A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24 weeks to children between 3 months and 12 years of age.
- Trial name
- NCT00000716
- Testing
- Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MOTIVATE 1 (NCT00098306)
- Testing
- Maraviroc (UK-427,857), Optimized Background Therapy
- Where
- 22 sites in United States, Canada
- Volunteers
- 601 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses.
- Trial name
- NCT00001015
- Testing
- Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Depression
Maternal Depression Treatment in HIV
Cluster randomized controlled trial to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the prevention of mother-to-child-transmission (PMTCT) care cascade at 8…
- Trial name
- M-DEPTH (NCT03892915)
- Testing
- evidence-based depression treatment
- Where
- Uganda
- Volunteers
- 391 people
- Sponsor
- RAND
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
This study is designed to evaluate the efficacy and safety of clarithromycin given orally at 1 of 3 doses to treat disseminated Mycobacterium avium complex infections (MAC) in patients with AIDS.
- Trial name
- NCT00000644
- Testing
- Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Universal Coverage of Antiretroviral Treatment in Senegal
Senegal plans a rapid scale up of HIV treatment for all people living with HIV, regardless of cluster of differentiation 4 (CD4) count or viral suppression.
- Trial name
- NCT03880006
- Testing
- Case management
- Where
- 4 sites in Senegal
- Volunteers
- 596 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infection, HIV Infections
Testing an HIV Prevention Intervention for Psychiatric Patients in Brazil
This study will test the effectiveness of a program aimed at reducing behaviors that increase HIV risk among people with severe mental illnesses.
- Trial name
- NCT00881699
- Testing
- HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you, Health Promotion Intervention
- Where
- Brazil
- Volunteers
- 460 people
- Sponsor
- New York State Psychiatric Institute
HIV Infections
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Dolutegravir (DTG), a human immunodeficiency virus (HIV)-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are each approved in the United States (US), European…
- Trial name
- NCT03984838
- Testing
- JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who…
- Trial name
- NCT00063804
- Testing
- Ritonavir, AMD070
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV Infections
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients
HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome.
- Trial name
- HB01EMVIPEG (NCT00391638)
- Testing
- TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a)
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hemophilia, AIDS
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Background: Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the natural history of these chronic…
- Trial name
- NCT00340548
- Where
- 15 sites in United States
- Volunteers
- 333 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Effect of Interleukin-2 on HIV Treatment Interruption
Interleukin-2 (IL-2) helps the body make infection-fighting white blood cells, including CD4 and CD8 T cells. One HIV treatment strategy is planned treatment interruption (stopping anti-HIV drugs when CD4 count and level of virus…
- Trial name
- NCT00015704
- Testing
- Aldesleukin
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Depression
Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
The purpose of this study is to test the efficacy of Our Family Our Future, an integrated intervention for preventing HIV and depression onset among adolescents.
- Conditions
- Human Immunodeficiency Virus, Depression, Sexually Transmitted Diseases
- Trial name
- NCT03231358
- Testing
- Our Family Our Future
- Where
- South Africa
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- Brown University
HIV Infection
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
- Trial name
- NCT00710593
- Testing
- HPV vaccine for strains -6, -11, -16, and -18
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 99 people
- Sponsor
- University of North Carolina, Chapel Hill
Mycobacterium Avium-intracellulare Infection, HIV Infections
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the…
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Trial name
- NCT00000933
- Where
- 15 sites in United States
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Subjects, Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01366547
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, AIDS
Once Daily 3TC, Efavirenz and ddI for HIV Infection
Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a randomised, multi-centre, open-label study in well-controlled treatment-experienced HIV-infected patients to assess compliance with a…
- Trial name
- NCT00214435
- Testing
- once daily minimum 3-drug regimen of anti-retroviral medications
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- 407 Doctors
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.